Brain serotonin neurotransmission: An overview and update with an emphasis on serotonin subsystem heterogeneity, multiple receptors, interactions with other neurotransmitter systems, and consequent implications for understanding the actions of serotonergic drugs

Journal of Clinical Psychiatry

Volumn 59, Issue SUPPL. 15, 1998, Pages 4-12

  Murphy, Dennis L ^a   Andrews, Anne M ^a   Wichems, Christine H ^a   Li, Qian ^a   Tohda, Michihisa ^a   Greenberg, Benjamin ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSPIRONE; CITALOPRAM; CLOMIPRAMINE; DOPAMINE; FENFLURAMINE; FLUOXETINE; GRANISETRON; ONDANSETRON; PAROXETINE; SEROTONIN; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SPIPERONE; SUMATRIPTAN; SUMATRIPTAN SUCCINATE; TRYPTOPHAN; UNCLASSIFIED DRUG; ZOTRAN;

DRUG MECHANISM; GENE EXPRESSION; HUMAN; MOLECULAR INTERACTION; NEUROPHYSIOLOGY; NEUROTRANSMISSION; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; SEROTONINERGIC SYSTEM; SIGNAL TRANSDUCTION;

ANIMALS; BRAIN; BRAIN CHEMISTRY; DEPRESSIVE DISORDER; GENE EXPRESSION; HORMONES; HUMANS; MENTAL DISORDERS; MICE; MICE, TRANSGENIC; NEUROTRANSMITTER AGENTS; RECEPTORS, NEUROTRANSMITTER; RECEPTORS, SEROTONIN; SEROTONIN; SEROTONIN AGENTS; SEROTONIN UPTAKE INHIBITORS; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION;

EID: 0031671214     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (118)

1. Chojnacka-Wojcik E. 5-hydroxytryptamine in the central nervous system. Pol J Pharmacol 1995;47:219-235
2. Semple-Rowland SL, Mahatme A, Rowland NE. Effects of dexfenfluramine or 5,7-dihydroxytryptamine on tryptophan hydroxylase and serotonin transporter mRNAs in rat dorsal raphe. Brain Mol Brain Res 1996;41: 121-127
3. Andrews AM, Murphy DL. 2′-NH2-MPTP in Swiss Webster mice: evidence for long-term (6-month) depletion in cortical and hippocampal serotonin and norepinephrine, differential protection by selective uptake inhibitors or clorgyline and functional changes in central serotonin transmission. J Pharmacol Exp Ther 1993;267:1432-1439
4. Lesch K-P, Bengel D, Heils A, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996;274:1527-1531
5. 2 receptors in the rat brain. J Psychiatry Neurosci 1993;19:63-67
6. 1A receptor sensitivity. Psychopharmacology 1997;132: 296-302
7. Frazer A. Pharmacology of antidepressants. J Clin Psychopharmacol 1997; 17:2S-18S
8. Peroutka SJ, Howell TA. The molecular evolution of G protein-coupled receptors: focus on 5-hydroxytryptamine receptors. Neuropharmacology 1994;33:319-324
9. Weiger WA. Serotonergic modulation of behaviour: a phylogenetic overview. Biol Rev Camb Philos Soc 1997;72:61-95
10. 2 serotonin receptor: coexpression with fushi-tarazu during segmentation. Proc Natl Acad Sci U S A 1995;692:5441-5445
11. Saudou F, Boschert U, Amlaiky N, et al. A family of Drosophila serotonin receptors with distinct intracellular signaling properties and expression patterns. EMBO J 1992;11:7-17
12. Papadopoulos GC, Pamavelas JG. Monoamine systems in the cerebral cortex: evidence for anatomical specificity. Prog Neurobiol 1991;36:195-200
13. Saudou F, Hen R. 5-Hydroxytryptamine receptor subtypes in vertebrates and invertebrates. Neurochem Int 1994;25:503-532
14. 1B receptor. Science 1994;265:1875-1878
15. Peroutka SJ. Molecular biology of serotonin (5-HT) receptors. Synapse 1994;18:241-260
16. 7 receptor: orphan found. Trends Pharmacol Sci 1997;18:104-107
17. Mazzola-Pomietto P, Aulakh CS, Huang SJ, et al. Repeated administration of meta-chlorophenylpiperazine or 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane produces tolerance to its stimulatory effect on adrenocorticotropin hormone but not prolactin or corticosterone secretion in rats. J Pharmacol Exp Ther 1996;279:782-789
18. 2A/2C receptor antagonists. Psychopharmacology 1997;130:144-151
19. el Mansari M, Blier P. In vivo electrophysiological characterization of 5-HT receptors in the guinea pig head of caudate nucleus and orbitofrontal cortex. Neuropharmacology 1997;36:577-588
20. 2C receptor antagonist. Neuropharmacology 1997;36: 609-620
21. 3 receptors. In: Jenner P, ed. Neuroscience Perspectives. San Diego, Calif: Academic Press Inc; 1992
22. 6 serotonin receptor. J Neurochem 1996;66:47-56
23. 7 receptor binding sites in rat hypothalamus: sensitivity to chronic antidepressant treatment. Mol Pharmacol 1995;47:99-103
24. 7 receptors mediate serotonergic effects on light-sensitive suprachiasmatic nucleus neurons. Brain Res 1997;755:246-254
25. 1B receptors. Nature 1992;360:161-163
26. Hoyer D, Martin G. 5-HT receptor classification and nomenclature: towards a harmonization with the human genome. Neuropharmacology 1997;36:419-428
27. 1D (BRL-15572) receptor ligands on guinea-pig and human 5-HT auto-and heteroreceptors. Naunyn Schmiedebergs Arch Pharmacol 1997;356:321-327
28. Watson JM, Burton MJ, Price GW, et al. GR127935 acts as a partial agonist at recombinant human 5-HT1D alpha and 5-HT1D beta receptors. Eur J Pharmacol 1996;314:365-372
29. 1D receptor subtypes. Trends Pharmacol Sci 1996;17:103-105
30. 1B/D receptor antagonists. Gen Pharmacol 1997;29: 293-303
31. 1D receptors. Naunyn Schmiedebergs Arch Pharmacol 1997;356:312-320
32. Jacobs BL, Azmitia EC. Structure and function of the brain serotonin system. Physiol Rev 1992;72:165-229
33. Kosofsky BE, Molliver ME. The serotoninergic innervation of cerebral cortex: different classes of axon terminals arise from dorsal and median raphe nuclei. Synapse 1987;1:153-168
34. Azmitia EC, Whitaker-Azmitia PM. Anatomy, cell biology, and plasticity of the serotonergic system. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1995:443-449
35. Mongeau R, Blier P, de Montigny C. The serotonergic and noradrenergic systems of the hippocampus: their interactions and the effects of antidepressant treatments. Brain Res Rev 1997;23:145-195
36. Mamounas LS, Mullen CA, O'Hearn E, et al. Dual serotonergic projections to forebrain in the rat: morphologically distinct 5-HT axon terminals exhibit differential vulnerability to neurotoxic amphetamine derivatives. J Comp Neurol 1991;314:558-586
37. 1A autoreceptors of the dorsal and median raphe nuclei. Synapse 1997;25:107-116
38. Invernizzi R, Carli M, Di Clemente A, et al. Administration of 8-hydroxy2-(Di-n-propylamino)tetralin in raphe nuclei dorsalis and medianus reduces serotonin synthesis in the rat brain: differences in potency and regional sensitivity. J Neurochem 1991;56:243-247
39. 1 receptors modulating transmitter release in rat cerebellum. J Pharmacol Exp Ther 1986;237:644-648
40. 1A receptors respectively mediate inhibition of glutamate release and inhibition of cyclic GMP production in rat cerebellum in vitro. J Neurochem 1996;66:203-209
41. Marcoli M, Maura G, Tortarolo M, et al. Serotonin inhibition of the NMDA receptor/nitnc oxide/cyclic GMP pathway in rat cerebellum: involvement of 5-hydroxytryptamine2C receptors. J Neurochem 1997;69:427-430
42. Lou JS, Goldfarb L, McShane L, et al. Use of buspirone for treatment of cerebellar ataxia: an open-label study. Arch Neurol 1995;52:982-988
43. Trouillas P, Fuxe K. Serotonin, the Cerebellum, and Ataxia. New York, NY: Raven Press; 1993
44. Abramowski D, Rigo M, Due D, et al. Localization of the 5-hydroxytryptamine2C receptor protein in human and rat brain using specific antisera. Neuropharmacology 1995;34:1635-1645
45. Erspamer V. Pharmacology of indole alkylamines. Pharmacol Rev 1954;6: 425-487
46. Russo AF, Clark MS, Durham PL. Thyroid parafollicular cells: an accessible model for the study of serotonergic neurons. Mol Neurobiol 1996;13: 257-276
47. James KM, Bryan-Lluka LJ. Efflux studies allow further characterisation of the noradrenaline and 5-hydroxytryptamine transporters in rat lungs. Naunyn Schmiedebergs Arch Pharmacol 1997;356:126-133
48. Lesch KP, Wolozin BL, Murphy DL, et al. Primary structure of the human platelet serotonin uptake site: identity with the brain serotonin transporter. J Neurochem 1993;60:2319-2322
49. Lu G, Unge T, Owera-Atepo JB, et al. Characterization and partial purification of human monoamine oxidase-B expressed in Escherichia coli. Protein Expr Purif 1996;7:315-322
50. Rapport MM, Green AA, Page IH. Serum vasoconstrictor (serotonin): isolation and characterization. J Biol Chem 1948;176:1243-1251
51. Abenhaim L, Moride Y, Brenot F. Appetite suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996;335:609-616
52. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;28:581-588
53. Schmidt CJ. Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. J Pharmacol Exper Ther 1987;240:1-7
54. McCann UD, Yuan J, Hatzidimitriou G, et al. Selective serotonin reuptake inhibitors dissociate fenfluramine's anorectic and neurotoxic effects: importance of dose, species and drug. J Pharmacol Exp Ther 1997;281: 1487-1498
55. McCann UD, Seiden LS, Rubin LJ, et al. Brain serotonin neurotoxicity and primary pulmonary hypertension from fenfluramine and dexfenfluramine: a systematic review of evidence. JAMA 1997;278:666-672
56. Molliver DC, Molliver ME. Anatomic evidence of a neurotoxic effect of (+/-)-fenfluramine upon serotonergic projections in the rat. Brain Res 1990;511:165-168
57. Simantov R, Tauber M. The abused drug MDMA (ecstasy) induces programmed death of human serotonergic cells. FASEB J 1997;11:141-146
58. Berger UV, Gu XF, Azmitia EC. The substituted amphetamines 3,4-methylenedioxymethamphetamine, methamphetamine, p-chloroamphetamine and fenfluramine induce 5-hydroxytryptamine release via a common mechanism blocked by fluoxetine and cocaine. Eur J Pharmacol 1992;215: 153-160
59. Verbeuren TJ. Synthesis, storage, release, and metabolism of 5-hydroxytryptamine in peripheral tissues. In: Fozard JR, ed. The Peripheral Actions of 5-hydroxytryptamine. Oxford, England: Oxford University Press; 1989:1-25
60. Gershon MD, Kirchgessner AL, Wade PR. Functional anatomy of the enteric nervous system. In: Johnson LRC, Alpers DH, Jacobson ED, et al, eds. Physiology of the Gastrointestinal Tract. New York, NY: Raven Press; 1994:381-422
61. Galligan JJ. Electrophysiological studies of 5-hydroxytryptamine receptors on enteric neurons. Behav Brain Res 1996;73:199-201
62. Graf S, Sarna SK. 5-HT-induced jejunal motor activity: enteric locus of action and receptor subtypes. Am J Physiol 1996;270:G992-G1000
63. Graf S, Sarna SK. 5-HT-induced colonic contractions: enteric locus of action and receptor subtypes. Am J Physiol 1997;273:G68-G74
64. Sha L, Ou LL, Miller SM, et al. Cat pancreatic neurons: morphology, electrophysiological properties, and responses to 5-HT. Pancreas 1996;13: 111-124
65. Masuda M, Miyasaka K, Funakoshi A. Involvement of 5-hydroxytryptamine (5-HT), receptor mechanisms in regulation of basal pancreatic secretion in conscious rats. J Auton Nerv Syst 1997;62:58-62
66. Noyer CM, Schwartz BM. Sertraline, a selective serotonin reuptake inhibitor, unmasking carcinoid syndrome. Am J Gastroenterol 1997;92: 1387-1388
67. Parsons AA, Parker SG, Raval P, et al. Comparison of the cardiovascular effects of the novel 5-HT (1B/1D) receptor agonist, SB 209509 (VML251), and sumatriptan in dogs. J Cardiovasc Pharmacol 1997;30:136-141
68. Cohen Z, Bonvento G, Lacombe P, et al. Serotonin in the regulation of brain microcirculation. Prog Neurobiol 1996;50:335-362
69. 4 receptor cloned from human atrium. FEBS Lett 1997;412:465-474
70. Ullmer C, Schmuck K, Kalkman HO, et al. Expression of serotonin receptor mRNAs in blood vessels. FEBS Lett 1995;370:215-221
71. Pierce PA, Xie GX, Levine JD, et al. 5-Hydroxytryptamine receptor subtype messenger RNAs in rat peripheral sensory and sympathetic ganglia: a polymerase chain reaction study. Neuroscience 1996;70:553-559
72. 1A receptors as a common pharmacologic link. J Clin Psychiatry 1997;58(suppl 8):20-26
73. Katz MM, Koslow SH, Frazer A. Onset of antidepressant activity: reexamining the structure of depression and multiple actions of drugs. Depress Anxiety 1996-1997;4:257-267
74. Owens MJ. Molecular and cellular mechanisms of antidepressant drugs. Depress Anxiety 1996-1997;4:153-159
75. 2C receptor in glial cells. Brain Res Bull 1995;38:153-159
76. 2C receptor. Psychopharmacology 1996;126:234-240
77. 2C receptors in the rat choroid plexus. Neuropsychopharmacology 1996;15:143-151
78. 2 receptor regulation of acetylcholine release induced by dopaminergic stimulation in rat striatal slices. Brain Res 1997;757:17-23
79. 1B presynaptic heteroreceptors inhibiting acetylcholine release. Neuropharmacology 1994;33:77-81
80. 3 receptors. J Neurochem 1994;62:2254-2261
81. Lane RM. Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors. Int Clin Psychopharmacol 1996;11(5, suppl):31-61
82. Launay JM, Callebert J, Bondoux D, et al. Serotonin receptors and therapeutics. Cell Mol Biol 1994;40:327-336
83. Richelson E. Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs. Mayo Clin Proc 1997;72:835-847
84. Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors: an overview with emphasis on pharmacokinetics and effects on oxidative metabolism. Clin Pharmacokinet 1997;32(1, suppl): 1-21
85. Wynshaw-Boris A. Model mice and human disease. Nat Genet 1996;13: 259-260
86. Crawley JN, Belknap JK, Collins A, et al. Behavioral phenotypes of inbred mouse strains: implications and recommendations for molecular studies. Psychopharmacology 1997;132:107-124
87. Gerlai R. Gene-targeting studies of mammalian behavior: is it the mutation or the background genotype? Trends Neurosci 1996;19:177-181
88. Hen R. Mean genes. Neuron 1996;16:17-21
89. Lucas JJ, Hen R. New players in the 5-HT receptor field: genes and knockouts. Trends Pharmaeol Sci 1995;16:246-252
90. Son JH, Joh TH. Genetically engineered neural transmission. Mol Psychiatry 1997;2:26-31
91. 2C serotonin receptors. Nature 1995;374:542-546
92. 2C receptor mutant mice. Nat Genet 1997;16:387-390
93. Murphy DL, Lesch KP, Aulakh CS, et al. Serotonin-selective arylpiperazines with neuroendocrine, behavioral, temperature, and cardiovascular effects in humans. Pharmacol Rev 1991;43:527-552
94. 2C receptors, respectively. Neuropsychopharmacology 1995;13:1-8
95. 1C receptors and their therapeutic relevance. Curr Opin Invest Drugs 1993;2:317-362
96. 1B receptors: in vivo microdialysis studies. J Neurochem 1997;69: 2019-2025
97. Cases O, Seif I, Grimsby J, et al. Aggressive behavior and altered amounts of brain serotonin and norepinephrine in mice lacking MAOA. Science 1995;268:1763-1766
98. Cases O, Vitalis T, Seif I, et al. Lack of barrels in the somatosensory cortex of monoamine oxidase A-deficient mice: role of a serotonin excess during the critical period. Neuron 1996;16:297-307
99. Kim JJ, Shih JC, Chen K, et al. Selective enhancement of emotional, but not motor, learning in monoamine oxidase A-deficient mice. Proc Natl Acad Sci U S A 1997;94:5929-5933
100. Chen C, Rainnie DG, Greene RW, et al. Abnormal fear response and aggressive behavior in mutant mice deficient for alpha-calcium-calmodulin kinase II. Science 1994;266:291-294
101. Chen C, Tonegawa S. Biochemical underpinnings of behavioral abnormalities in mice. J NIH Research 1994;7:50-51
102. Mayford M, Bach ME, Huang YY, et al. Control of memory formation through regulated expression of a CaMKII transgene. Science 1996;274: 1678-1683
103. Hilakivi-Clarke LA, Goldberg R. Effects of tryptophan and serotonin uptake inhibitors on behavior in male transgenic transforming growth factor alpha mice. Eur J Pharmacol 1993;237:101-108
104. A receptors in transgenic mice overexpressing TGF alpha. Pharmacol Biochem Behav 1995;50:593-600
105. Bengel D, Murphy DL, Andrews AM, et al. Altered brain serotonin (5-HT) homeostasis and locomotor insensitivity to MDMA ("ecstasy") in 5-HT transporter-deficient mice. Mol Pharmacol. In press
106. Andrews AM, Wichems CH, Bengel D, et al. The effects of MDMA on monoamine neurotransmitter levels and temperature in mice with disrupted serotonin transporter. Soc Neurosci Abs 1997;23:980
107. 1A receptor. Soc Neurosci Abs 1997;23:980
108. Moiseiwitsch JR, Lauder JM. Serotonin regulates mouse cranial neural crest migration. Proc Natl Acad Sci U S A 1995;92:7182-7186
109. Shuey DL, Sadler TW, Lauder JM. Serotonin as a regulator of craniofacial morphogenesis: site specific malformations following exposure to serotonin uptake inhibitors. Teratology 1992;46:367-378
110. Nulman I, Rovet J, Stewart DE, et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 1997;336:258-262
111. Chambers CD, Johnson KA, Dick LM, et al. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996;335:1010-1015
112. Robert E. Treatment depression in pregnancy. N Engl J Med 1996;335: 1056-1058
113. Giros B, Jaber M, Jones SR, et al. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 1996;379:606-612
114. Bennett-Clarke CA, Chiaia NL, Rhoades RW. Contributions of raphecortical and thalamocortical axons to the transient somatotopic pattern of serotonin immunoreactivity in rat cortex. Somatosens Mot Res 1997;14: 27-33
115. Tilakaratne N, Yang Z, Friedman E. Chronic fluoxetine or desmethylimipramine treatment alters 5-HT, receptor mediated c-fos gene expression. Eur J Pharmacol 1995;15:263-266
116. Hyman SE, Nestler EJ. Initiation and adaptation: a paradigm for understanding psychotropic drug action. Am J Psychiatry 1996;153:151-162
117. Burns CM, Chu H, Rueter SM, et al. Regulation of serotonin-2C receptor G-protein coupling by RNA editing. Nature 1997;387:303-308
118. 1A agonist. J Pharmacol Exp Ther 1996;279:1035-1042